Drugs / CT-P52
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07367958 | Jan → Jul 2026 | — | Celltrion | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-P52 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07367958 ↗ |
| Known as | ixekizumab | “CT-P52, containing the active ingredient ixekizumab, is being developed by CELLTRION, Inc. as a proposed biosimilar to the reference product, Taltz.” NCT07367958 ↗ |
| Route | Subcutaneous | “a single subcutaneous (SC) injection via auto-injector (AI)” NCT07367958 ↗ |